Novo Nordisk A/S (NYSE: NVO) has filed lawsuits against several medical spas, weight-loss clinics, and wellness clinics, alleging they illegally marketed custom-made versions of Ozempic and other Novo Nordisk medicines for weight loss.
Merck & Co Inc (NYSE: MRK) announced topline results from the Phase 3 KEYNOTE-585 trial of Keytruda (pembrolizumab) in combination with chemotherapy as a
Eli Lilly And Co (NYSE: LLY) has agreed to acquire DICE Therapeutics Inc (NASDAQ: DICE), a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop oral therapeutic ca
Danish pharmaceutical company Novo Nordisk A/S (NYSE: NVO) announced that introducing its obesity drug Wegovy in most European countries will experience delays, and the drug is not expected to be available in developing nations for an extended period.